Ionis Pharmaceuticals Q2 2025 Earnings Call Transcript

Ionis Pharmaceuticals reported Q2 2025 earnings, with CEO Brett Monia and CFO Beth Hougen discussing financial results and product developments. The company's net revenue increased to $133.4 million, driven by strong sales of SPINRAZA and TEGSEDI. Ionis also highlighted progress in its clinical pipeline, including positive data from the CARMINE trial for AKCEA-APOCIII-LRx. The company's non-GAAP net income was $32.1 million, or $0.88 per share.

Ionis Pharmaceuticals Inc. (IONS) reported its second-quarter 2025 financial results, with a significant improvement in earnings and revenue. The company's adjusted earnings per share (EPS) came in at $0.85, compared to the expected loss of $0.52, and the revenue reached $452 million, surpassing the consensus estimate of $282.95 million [1].

The strong performance was driven by the successful launch of Tryngolza (olezarsen), the first FDA-approved treatment for familial chylomicronemia syndrome, and increased royalty and R&D revenues. Tryngolza generated net product sales of $19 million in the second quarter, contributing to the overall revenue growth [1].

The company also highlighted progress in its clinical pipeline, including positive data from the CARMINE trial for AKCEA-APOCIII-LRx. Additionally, the drug received a positive opinion from the Committee for Medicinal Products for Human Use, paving the way for its approval in Europe [1].

Ionis raised its fiscal 2025 sales guidance to $825 million-$850 million, compared to the previous estimate of $725 million-$750 million. The company expects a 2025 adjusted operating loss of $300 million-$325 million, with cash, cash equivalents, and short-term investments of around $2 billion [1].

The stock price of Ionis Pharmaceuticals has seen a positive reaction to the earnings report, with the stock up 5.23% at $43.65 at publication [1].

References:
[1] https://www.benzinga.com/markets/earnings/25/07/46733874/ionis-posts-surprise-q2-profit-double-revenues-on-stronger-sales-from-newly-approved-genetic-disease-drug
[2] https://www.gurufocus.com/news/3016122/ionis-reports-second-quarter-2025-financial-results-and-highlights-progress-on-key-programs